Background: Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor receptor-2 (VEGFR-2). An initial phase I study evaluated ramucirumab administered weekly in advanced cancer patients. This phase I study of ramucirumab [administered every 2 or 3 weeks (Q2W or Q3W)] examined safety, maximum tolerated dose, pharmacokinetics, immunogenicity, antitumor activity, and pharmacodynamics.
introduction Vascular endothelial growth factor (VEGF) is involved in cancer growth and metastasis, and enables tumors to establish vascular networks. Multiple VEGF ligands (placental growth factor, VEGF-A through VEGF-E) and VEGF receptors (VEGFR-1, -2, and -3) on the surface of endothelial cells are involved in angiogenesis [1] . VEGF-A binding to VEGFR-1 and VEGFR-2 has been shown to stimulate neo-angiogenesis and tumor permeability. VEGF-C and -D that bind VEGFR-3 and -2 have also been shown to have important roles in angiogenesis and lymphangiogenesis [2, 3] . VEGFR-2 is critical for angiogenesis and also involved in lymphangiogenesis [4] , and is frequently overexpressed in tumors versus normal vasculature, and is a critical receptor involved in endothelial intracellular signaling. Inhibition of VEGFR-2 signaling by anti-VEGF-A or anti-VEGFR-2 antibodies or small-molecule VEGFR tyrosine kinase inhibitors has been shown to inhibit tumor growth and has conferred clinical activity in various solid tumors. While several anti-VEGF antibodies and multitargeted VEGFR tyrosine kinase inhibitors are utilized in clinical practice, few agents that directly and specifically inhibit only VEGFR-2 have been evaluated [5, 6] .
Ramucirumab (IMC-1121B) is a fully human immunoglobulin G1 monoclonal antibody that selectively blocks human VEGFR-2 with high affinity (50 pM), reducing endothelial cell permeability, migration, and proliferation [7, 8] . In addition, ramucirumab may mediate anticancer effects through antibodydependent cytotoxicity [9] . A previous phase I study evaluated 2-16-mg/kg weekly doses of ramucirumab; the maximum tolerated dose (MTD) was 13 mg/kg [10] .
This multicenter phase I study evaluated the safety profile and MTD of ramucirumab administered every 2 (Q2W) or 3 weeks (Q3W) for patients with advanced solid malignancies. Secondary objectives included the characterization of the pharmacokinetic profile, immunogenicity, pharmacodynamic effects related to angiogenic markers, and preliminary antitumor activity.
methods study design
Details regarding patient selection have been described [10] . Ramucirumab was administered in escalating doses as a 1-h i.v. infusion (≤25 mg/min), Q2W (cohorts 1-3) in 4-week cycles, or Q3W (cohorts 4, 5) in 3-week cycles. The doses in cohorts 1, 2, and 3 were 6, 8, and 10 mg/kg, respectively; the first treatment cycle was preceded by an initial dose of ramucirumab and a 2-week pharmacokinetic sampling period, followed by two infusions of ramucirumab Q2W and a 2-week observation period (8 weeks total; 3 infusions). Cohorts 1-3 each initially enrolled two patients. If neither patient experienced a dose-limiting toxicity (DLT) during the 4-week treatment period, two additional patients were to be enrolled. When all patients completed a cohort, dose escalation to the next higher dose level occurred. In cohorts 4 and 5 (15-and 20-mg/kg doses, enrolled simultaneously), ramucirumab was administered Q3W, with a 3 + 3 dose-escalation design. Once three patients in each cohort completed two treatment cycles, and in the absence of DLT, three additional patients in both cohorts 4 and 5 were enrolled in a nonblinded alternating fashion.
The MTD was defined as the dose below the dose level at which two patients experienced a DLT during the first treatment cycle (8 weeks) in cohorts 1-3, or the first two treatment cycles (6 weeks) for Cohorts 4 and 5. A DLT was defined as any grade 4 neutropenia lasting >7 days; grade 3 febrile neutropenia, thrombocytopenia, or anemia; or any grade ≥3 drugrelated nonhematologic toxicity. Up to two dose reductions per patient were permitted. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 3).
Treatment assessment, pharmacokinetic, and pharmacodynamic methods are found in Supplementary Materials, available at Annals of Oncology online. , and all 12 patients treated in cohorts 4-5 completed at least two cycles (6 weeks). Among the three patients who did not complete cycle 1, two had disease progression (both cohort 1) and one had an AE (cohort 2, cycle 1, day 8, hypertension and transient ischemic attack (TIA) thought unrelated to study drug and due to prior history of hypertension). Reasons for study discontinuation were: disease progression (n = 15, 60%), clinical deterioration without documented radiologic progression (n = 1, 4%), adverse events (AEs; n = 5, 20%), withdrawal of consent or 'unknown reason' (each n = 2, 8%). Demographic and disease characteristics are displayed in Table 1 . Patients received a median of four ramucirumab infusions (range of 1-31). The median dose intensity was 4.8 mg/kg/week and the median relative dose intensity was 100%; 22/25 patients received a relative dose intensity of ≥90%.
toxicity
No DLTs were identified; therefore, the MTD was not identified at the doses and schedules tested in this study. A total of 18 (72%) patients had at least one AE possibly related to ramucirumab. Proteinuria and hypertension (24% each); diarrhea, fatigue, and headache (16% each); and vomiting and peripheral edema (12% each) were the most frequently reported ramucirumab-related AEs (Table 2 ). Five patients (20%) had one or more grade 3-4 ramucirumab-related AEs, including two patients with grade 3 hypertension (cohorts 3 and 5). Of the related grade 3-4 AEs, all were grade 3 except duodenal ulcer hemorrhage and pneumothorax, and most were in the higher dose cohorts (3-5) ( Table 2) . Dose modification (reduction or hold) of ramucirumab due to an AE was applied to 10 patients. Five patients discontinued the study due to an AE: grade 4 duodenal ulcer hemorrhage (cohort 2); grade 3 hypertension and TIA (cohort 2); grade 2 proteinuria (cohort 3); grade 4 myocardial infarction (day 167, following 7 infusions) (cohort 5); and grade 3 dyspnea with grade 4 pneumothorax (cohort 5). Additionally, a patient (cohort 1) with pancreatic adenocarcinoma (diagnosed 11 months before study entry) died from progressive disease on study, 26 days after receiving a third infusion of ramucirumab.
pharmacokinetics
Mean pharmacokinetic parameters derived from noncompartmental analyses of ramucirumab concentration over time after one or three ramucirumab cycle 1 infusions (Table 3 ) are characterized by low clearance (CL), a V ss consistent with total blood volume (∼30-60 ml/kg), and long half-life (t 1/2 ) of 110-160 h. Clearance appeared to be similar across dose levels. Following a single ramucirumab dose, the maximum serum concentration (C max ) and area under the concentration-time curve measures (AUC) generally increase with dose as expected. The limited pharmacokinetics sampling schedule (2 weeks for the 6-10 mg/kg, and 3 weeks for the 15-and 20-mg/kg groups) may not accurately capture the true terminal half-life. [10] . Among these patients, three had stable disease as best response, lasting 15-63 weeks.
Serum biomarkers. Figure 1A -C depicts the serum concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 after the first ramucirumab infusion. VEGF-A concentrations increased immediately after treatment and in general, remained elevated two-to eight-fold from baseline at 7 days. For patients treated for multiple cycles, VEGF-A showed persistent elevation. sVEGFR-1 remained relatively constant although some patients exhibited elevated levels. sVEGFR-2 concentrations tended to decrease after ramucirumab treatment, generally recovering to pretreatment levels within 2-4 days. With repeat dosing (≥4 weeks on study) patients in some cohorts exhibited sVEGFR-2 levels 40%-100% higher than prestudy levels. For all serum biomarkers, the observed changes in levels did not appear to be dose-related.
immunogenicity
Of the 25 patients with pre-and post-treatment samples evaluated, three patients developed anti-ramucirumab antibodies:
two patients at cycle 2 before infusion (15 and 20 mg/kg Q3W) and one patient at follow-up (6 mg/kg Q2W). None of these anti-ramucirumab antibodies were neutralizing.
antitumor activity
No partial or complete responses were observed. Fifteen patients (60%) had a best response of stable disease with a median duration of 12.7 months (range 1.7-18 months) across all cohorts. Stable disease lasting ≥4 months occurred in one of five patients (20%) (colorectal cancer), two of four patients (50%) (renal cell), two of three patients (67%) [liver and neuroendocrine 
discussion
This phase I study evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ramucirumab administered Q2W/Q3W in patients with advanced solid tumors. No DLTs were seen and the MTD was not identified. Recommended phase II doses of 8 mg/kg Q2W and 10 mg/kg Q3W were chosen based on the results from this study and those from the weekly dosing study [10] . Doses within this range yielded the minimum trough concentrations (C min ) that exceeded the 20-μg/ml levels associated with growth inhibition in preclinical human tumor xenograft models (data on file) and were associated with preliminary evidence of efficacy. In addition, doses of ≥8 mg/kg Q2W were associated with relatively stable clearance profiles (as opposed to more dose-dependent patterns seen at lower doses), consistent with saturation of the target-mediated (VEGFR-2) clearance pathway.
The toxicity profile was consistent with other anti-VEGF/ VEGFR therapies and included hypertension (8% grade 3, observed at the highest doses in each schedule: cohorts 3 and 5) and lymphopenia (8% grade 3 in cohort 3). All other AEs were grade 1 or 2 across dose levels. The AE profile in the current study suggests a relationship between dose/higher incidence of toxicity.
The pharmacokinetic profile for ramucirumab administered Q2W/Q3W is similar to that of other monoclonal immunoglobulin G1 antibodies used for cancer patient therapy [11] and comparable with the ramucirumab profile reported earlier [10] . The fairly steady and low clearance suggests that the VEGFR-2 receptors were saturated at all dosing regimens tested. As previously demonstrated with the QW schedule, VEGFR-2 blockade with ramucirumab led to an immediate and sustained increase in VEGF-A levels, suggesting ligand displacement from the VEGFR-2 receptors, although compensatory VEGF-A upregulation might also account for the increases. The clinical significance of these VEGF-A increases is uncertain. sVEGFR-2 levels decreased rapidly after treatment likely because both circulating and endothelial receptors are bound by ramucirumab, but recovered within 2-4 days, when serum ramucirumab levels are expected to decrease by binding to cellular VEGFR-2 and degradation. This is in contrast to VEGFR TKIs that induce a persistent decrease in sVEGFR-2 levels, pointing to their different mechanisms of action. In human cancers, VEGF-C and -D expression have been correlated with metastatic spread, mostly by stimulating lymphangiogenesis via VEGFR-3 activation, increasing neovascularization through VEGFR-2 [1, 12] , and by inducing an inflammatory tissue microenvironment [13] . Since ramucirumab directly binds VEGFR-2, it not only inhibits VEGF-A signaling, but also blocks binding by VEGF-C and VEGF-D that may enhance antitumor activity [14] . It is therefore possible that targeting VEGFR-2 may lead to a broader antiangiogenic and antitumor activity than can be obtained with VEGF-A blockade alone.
In this study, no partial responses were observed, but 60% of patients had durable stable disease (median duration of 13 months) across all cohorts, and 10 patients had SD ≥4 months (Figure 2) . Together with the phase I trial of ramucirumab QW ( partial responses occurred in gastric and ovarian cancers, melanoma, and leiomyosarcoma), the current data demonstrated disease control across a range of solid tumors and contributed to the rationale for several pivotal phase III studies with ramucirumab. Ramucirumab (8 mg/kg Q2W) conferred overall survival benefit in the second-line treatment of advanced gastric and gastroesophageal junction adenocarcinomas as single agent versus placebo (REGARD study) [15] , and in combination with paclitaxel versus paclitaxel/placebo (RAINBOW study) [16] . Additionally, the combination of ramucirumab (10 mg/kg Q3W) with docetaxel improved survival in second-line treatment of non-small-cell lung cancer in the REVEL phase III study [17] .
In summary, the highly selective anti-VEGFR-2 antibody ramucirumab is well tolerated and showed signs of clinical activity in this phase I study in patients with multiple solid tumors. Based on the pharmacokinetic/safety profiles of ramucirumab, phase II and III studies have mostly employed the 8-mg/kg Q2W or the 10-mg/kg Q3W dosing schedules. Similar to other anti-VEGF/VEGFR agents, biomarkers predictive of benefit have not yet been identified and would be helpful to optimize clinical utility. Since ramucirumab directly binds VEGFR-2, it not only affects VEGF-A signaling, but blocks interactions with VEGF-C and VEGF-D ligands. While measurement of these potential biomarkers presents many technical challenges, VEGF-C levels in plasma have also been correlated with disease progression on bevacizumab in a series of patients with metastatic colorectal cancer [18] . Similarly, in two separate large randomized studies, VEGF-D levels in plasma [19] and tumor tissue [20] have been identified as possible markers for lack of benefit from bevacizumab. These findings have yet to be validated; however, ongoing biomarker studies from multiple phase III studies with bevacizumab and ramucirumab are expected to clarify the relative roles of VEGF-A, VEGF-C, and VEGF-D in cancer biology and the potential for these markers to delineate mechanistically important differences between VEGF-A-and VEGFR-2-specific inhibitors. 
